Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Tiotropium / Respimat One Year Study in COPD.

7 maggio 2014 aggiornato da: Boehringer Ingelheim

Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD

The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

3991

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Australia
    • New South Wales
      • Glebe, New South Wales, Australia
        • 205.372.61002 Woolcock Institute of Medical Research
    • Queensland
      • Cairns, Queensland, Australia
        • 205.372.61009 Thoracic & General Physician
      • Redcliffe, Queensland, Australia
        • 205.372.61005 Redcliffe Hospital
    • South Australia
      • Port Lincoln, South Australia, Australia
        • 205.372.61006 The Investigator Clinic
      • Toorak Gardens, South Australia, Australia
        • 205.372.61007 The Burnside War Memorial Hospital
      • Woodville, South Australia, Australia
        • 205.372.61004 Boehringer Ingelheim Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia
        • 205.372.61010 Ecru
      • Geelong, Victoria, Australia
        • 205.372.61008 Geelong Clinical Research Centre
      • Malvern, Victoria, Australia
        • 205.372.61001 Emeritus Research
    • Western Australia
      • Nedlands, Western Australia, Australia
        • 205.372.61003 Sir Charles Gairdner Hospital
  • Brasile
      • Florianópolis, Brasile
        • 205.372.55012 Universidade Federal de Santa Catarina
      • Goiânia, Brasile
        • 205.372.55009 Hospital das Clínicas de Goiânia
      • Recife, Brasile
        • 205.372.55005 Hospital Geral Otávio de Freitas
      • São Paulo - SP, Brasile
        • 205.372.55001 INCOR e Hospital das Clínicas da Universidade de São Paulo
      • São Paulo - SP, Brasile
        • 205.372.55010 Unidade de Coracao e Pulmao do Dto. de Medicina
      • Vitória, Brasile
        • 205.372.55011 CEDOES - Diagnóstico e Pesquisa
  • Canada
    • Alberta
      • Calgary, Alberta, Canada
        • 205.372.11007 Heritage Medical Research Building
      • Calgary, Alberta, Canada
        • 205.372.11013 Calgary West Medical Centre
      • Edmonton, Alberta, Canada
        • 205.372.11011 Hermitage Medicentre
      • Edmonton, Alberta, Canada
        • 205.372.11017 Boehringer Ingelheim Investigational Site
      • Wetaskiwin, Alberta, Canada
        • 205.372.11020 Wetaskiwin Lung Laboratory
    • British Columbia
      • Chilliwack, British Columbia, Canada
        • 205.372.11010 Dr. Kay Ho
      • Vancouver, British Columbia, Canada
        • 205.372.11018 Pacific Lung Health Centre
    • New Brunswick
      • Saint John, New Brunswick, Canada
        • 205.372.11005 Professional Corp. Respirology
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada
        • 205.372.11009 White Hills Medical Clinic
    • Ontario
      • Grimsby, Ontario, Canada
        • 205.372.11012 West Lincoln Memorial Hospital
      • London, Ontario, Canada
        • 205.372.11014 Dr. Robert Luton
      • Niagara Falls, Ontario, Canada
        • 205.372.11001 Niagara Clinical Research
      • Ottawa, Ontario, Canada
        • 205.372.11019 Allergy and Asthma Research Centre
      • Sarnia, Ontario, Canada
        • 205.372.11003 London Road Diagnostic Clinic and Medical Centre
      • Sarnia, Ontario, Canada
        • 205.372.11016 London Road Diagnostic Clinic and Medical Centre
      • Scarborough, Ontario, Canada
        • 205.372.11002 Centenary Respiratory Research Associates
    • Quebec
      • La Malbaie, Quebec, Canada
        • 205.372.11006 Clinique de médecine familiale de La Malbaie
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada
        • 205.372.11004 Mount Royal Family Physicians
      • Saskatoon, Saskatchewan, Canada
        • 205.372.11015 Dr. Arun Nayar
  • Cina
      • Beijing, Cina
        • 205.372.86002 Boehringer Ingelheim Investigational Site
      • Beijing, Cina
        • 205.372.86003 Boehringer Ingelheim Investigational Site
      • Beijing, Cina
        • 205.372.86004 Boehringer Ingelheim Investigational Site
      • Chengdu, Sichuan Province, Cina
        • 205.372.86009 Boehringer Ingelheim Investigational Site
      • Chongqing, Cina
        • 205.372.86008 Boehringer Ingelheim Investigational Site
      • Guangzhou, Cina
        • 205.372.86001 Boehringer Ingelheim Investigational Site
      • Shanghai, Cina
        • 205.372.86010 Boehringer Ingelheim Investigational Site
      • Shanghai, Cina
        • 205.372.86011 Boehringer Ingelheim Investigational Site
      • Shanghai, Cina
        • 205.372.86012 Boehringer Ingelheim Investigational Site
      • Shenyang, Cina
        • 205.372.86005 Boehringer Ingelheim Investigational Site
      • Shenyang, Cina
        • 205.372.86006 Boehringer Ingelheim Investigational Site
      • Wuhan, Cina
        • 205.372.86007 Boehringer Ingelheim Investigational Site
  • Corea, Repubblica di
      • Anyang, Corea, Repubblica di
        • 205.372.82010 Boehringer Ingelheim Investigational Site
      • Daegu, Corea, Repubblica di
        • 205.372.82005 Boehringer Ingelheim Investigational Site
      • Daejoen, Corea, Repubblica di
        • 205.372.82009 Boehringer Ingelheim Investigational Site
      • Incheon, Corea, Repubblica di
        • 205.372.82003 Boehringer Ingelheim Investigational Site
      • Jeonbuk, Corea, Repubblica di
        • 205.372.82008 Boehringer Ingelheim Investigational Site
      • Kwangju, Corea, Repubblica di
        • 205.372.82007 Boehringer Ingelheim Investigational Site
      • Pusan, Corea, Repubblica di
        • 205.372.82002 Boehringer Ingelheim Investigational Site
      • Seoul, Corea, Repubblica di
        • 205.372.82001 Boehringer Ingelheim Investigational Site
      • Seoul, Corea, Repubblica di
        • 205.372.82004 Boehringer Ingelheim Investigational Site
      • Seoul, Corea, Repubblica di
        • 205.372.82006 Boehringer Ingelheim Investigational Site
  • Danimarca
      • Aarhus C, Danimarca
        • 205.372.45004 Boehringer Ingelheim Investigational Site
      • Horsens, Danimarca
        • 205.372.45005 Boehringer Ingelheim Investigational Site
      • Hvidovre, Danimarca
        • 205.372.45002 Boehringer Ingelheim Investigational Site
      • København NV, Danimarca
        • 205.372.45001 Boehringer Ingelheim Investigational Site
      • Odense C, Danimarca
        • 205.372.45003 Boehringer Ingelheim Investigational Site
      • Silkeborg, Danimarca
        • 205.372.45006 Boehringer Ingelheim Investigational Site
  • Finlandia
      • Helsinki, Finlandia
        • 205.372.35804 Boehringer Ingelheim Investigational Site
      • Jyväskylä, Finlandia
        • 205.372.35802 Boehringer Ingelheim Investigational Site
      • Lahti, Finlandia
        • 205.372.35803 Boehringer Ingelheim Investigational Site
      • Tampere, Finlandia
        • 205.372.35801 Boehringer Ingelheim Investigational Site
  • Francia
      • Castelnau le Lez, Francia
        • 205.372.3318A Clinique du Parc
      • Castelnau le Lez, Francia
        • 205.372.3318B Clinique du Parc
      • Chamalières, Francia
        • 205.372.3304A Cabinet Médical
      • Clermont Ferrand cedex 1, Francia
        • 205.372.3301A Hôpital Gabriel Montpied
      • Denain, Francia
        • 205.372.3310A Centre Hospitalier
      • Grasse, Francia
        • 205.372.3314A Cabinet Médical
      • Marseille, Francia
        • 205.372.3306A Hôpital Ambroise Paré
      • Metz cedex 1, Francia
        • 205.372.3303A Hôpital Notre Dame de Bon Secours
      • Metz cedex 1, Francia
        • 205.372.3303B Hôpital Notre Dame de Bon Secours
      • Montigny les Metz, Francia
        • 205.372.3312A Cabinet Médical
      • Montigny les Metz, Francia
        • 205.372.3312B Cabinet Médical
      • Nantes, Francia
        • 205.372.3302A Centre Médical Erdre Saint Augustin
      • Nice, Francia
        • 205.372.3305A Cabinet Médical
      • Nice, Francia
        • 205.372.3305B Cabinet Médical
      • Nimes cedex 9, Francia
        • 205.372.3315B Hôpital Caremeau
      • Nîmes, Francia
        • 205.372.3315A Hôpital Caremeau
      • Nîmes, Francia
        • 205.372.3317A Cabinet de Pneumologie
      • Ollioules, Francia
        • 205.372.3320A Polyclinique Les Fleurs
      • Ollioules, Francia
        • 205.372.3320B Polyclinique Les Fleurs
      • Reims, Francia
        • 205.372.3316A Clinique les Bleuets
      • Reims, Francia
        • 205.372.3316B Clinique les Bleuets
      • Saint Laurent du Var, Francia
        • 205.372.3319A Institut Arnault Tzanck
      • Six Four les Plages, Francia
        • 205.372.3325A Cabinet Médical
      • St Gaudens, Francia
        • 205.372.3321A Centre Hospitalier
      • St Gaudens, Francia
        • 205.372.3321C Centre Hospitalier
      • Toulon, Francia
        • 205.372.3324A Cabinet Médical
      • Toulouse, Francia
        • 205.372.3309A Cabinet médical
      • Toulouse, Francia
        • 205.372.3309B Cabinet médical
  • Germania
      • Berlin, Germania
        • 205.372.49002 Boehringer Ingelheim Investigational Site
      • Berlin, Germania
        • 205.372.49004 Boehringer Ingelheim Investigational Site
      • Berlin, Germania
        • 205.372.49013 Boehringer Ingelheim Investigational Site
      • Bonn, Germania
        • 205.372.49007 Boehringer Ingelheim Investigational Site
      • Bruchsal, Germania
        • 205.372.49008 Boehringer Ingelheim Investigational Site
      • Frankfurt/Main, Germania
        • 205.372.49011 Boehringer Ingelheim Investigational Site
      • Gelnhausen, Germania
        • 205.372.49012 Boehringer Ingelheim Investigational Site
      • Gütersloh, Germania
        • 205.372.49006 Boehringer Ingelheim Investigational Site
      • Hannover, Germania
        • 205.372.49014 Boehringer Ingelheim Investigational Site
      • Kassel, Germania
        • 205.372.49005 Boehringer Ingelheim Investigational Site
      • Minden, Germania
        • 205.372.49009 Boehringer Ingelheim Investigational Site
      • München, Germania
        • 205.372.49010 Boehringer Ingelheim Investigational Site
      • Weinheim, Germania
        • 205.372.49016 Boehringer Ingelheim Investigational Site
      • Weyhe, Germania
        • 205.372.49015 Boehringer Ingelheim Investigational Site
      • Wiesloch, Germania
        • 205.372.49001 Boehringer Ingelheim Investigational Site
      • Witten, Germania
        • 205.372.49003 Boehringer Ingelheim Investigational Site
  • Grecia
      • Athens, Grecia
        • 205.372.30001 Boehringer Ingelheim Investigational Site
      • Athens, Grecia
        • 205.372.30002 Boehringer Ingelheim Investigational Site
      • Athens, Grecia
        • 205.372.30003 Boehringer Ingelheim Investigational Site
      • Athens, Grecia
        • 205.372.30013 Boehringer Ingelheim Investigational Site
      • Athens, Grecia
        • 205.372.30015 Boehringer Ingelheim Investigational Site
      • Heraklion-Crete, Grecia
        • 205.372.30009 Boehringer Ingelheim Investigational Site
      • Kalamaria, Grecia
        • 205.372.30007 Boehringer Ingelheim Investigational Site
      • Kavala, Grecia
        • 205.372.30005 Boehringer Ingelheim Investigational Site
      • Komotini, Grecia
        • 205.372.30004 Boehringer Ingelheim Investigational Site
      • Korinthos, Grecia
        • 205.372.30011 Boehringer Ingelheim Investigational Site
      • Nafplio, Grecia
        • 205.372.30019 Boehringer Ingelheim Investigational Site
      • Serres, Grecia
        • 205.372.30008 Boehringer Ingelheim Investigational Site
      • Thessaloniki, Grecia
        • 205.372.30006 Boehringer Ingelheim Investigational Site
      • Thessaloniki, Grecia
        • 205.372.30017 Boehringer Ingelheim Investigational Site
      • Thiva, Grecia
        • 205.372.30014 Boehringer Ingelheim Investigational Site
  • Hong Kong
      • Hong Kong, Hong Kong
        • 205.372.85203 Boehringer Ingelheim Investigational Site
      • Kowloon, Hong Kong
        • 205.372.85201 Boehringer Ingelheim Investigational Site
  • India
      • Andhra Pradesh, India
        • 205.372.91005 Boehringer Ingelheim Investigational Site
      • Andhra Pradesh, India
        • 205.372.91016 Boehringer Ingelheim Investigational Site
      • Bangalore, India
        • 205.372.91003 Boehringer Ingelheim Investigational Site
      • Bangalore, India
        • 205.372.91006 Boehringer Ingelheim Investigational Site
      • Calicut,Kerala, India
        • 205.372.91017 Boehringer Ingelheim Investigational Site
      • Chennai, India
        • 205.372.91007 Boehringer Ingelheim Investigational Site
      • Chennai, India
        • 205.372.91010 Boehringer Ingelheim Investigational Site
      • Coimbatore, India
        • 205.372.91002 Boehringer Ingelheim Investigational Site
      • Gujarat, India
        • 205.372.91009 Boehringer Ingelheim Investigational Site
      • Maharashtra, India
        • 205.372.91012 Boehringer Ingelheim Investigational Site
      • Mumbai, India
        • 205.372.91004 Boehringer Ingelheim Investigational Site
      • Mumbai, India
        • 205.372.91008 Boehringer Ingelheim Investigational Site
      • New Delhi, India
        • 205.372.91015 Boehringer Ingelheim Investigational Site
      • Punjab, India
        • 205.372.91014 Boehringer Ingelheim Investigational Site
      • Tamil Nadu, India
        • 205.372.91013 Boehringer Ingelheim Investigational Site
      • Uttar Pradesh, India
        • 205.372.91001 Boehringer Ingelheim Investigational Site
      • indore,MP, India
        • 205.372.91011 Boehringer Ingelheim Investigational Site
  • Irlanda
      • Mullingar, Irlanda
        • 205.372.35303 Boehringer Ingelheim Investigational Site
  • Italia
      • Bussolengo (vr), Italia
        • 205.372.39007 Boehringer Ingelheim Investigational Site
      • Ferrara, Italia
        • 205.372.39012 Boehringer Ingelheim Investigational Site
      • Genova, Italia
        • 205.372.39003 Boehringer Ingelheim Investigational Site
      • Genova, Italia
        • 205.372.39004 Boehringer Ingelheim Investigational Site
      • Milano, Italia
        • 205.372.39005 Boehringer Ingelheim Investigational Site
      • Modena, Italia
        • 205.372.39008 Boehringer Ingelheim Investigational Site
      • Orbassano (to), Italia
        • 205.372.39009 Boehringer Ingelheim Investigational Site
      • Pisa, Italia
        • 205.372.39001 Boehringer Ingelheim Investigational Site
      • Pordenone, Italia
        • 205.372.39010 Boehringer Ingelheim Investigational Site
      • Prato (fi), Italia
        • 205.372.39002 Boehringer Ingelheim Investigational Site
      • Roma, Italia
        • 205.372.39011 Boehringer Ingelheim Investigational Site
      • Trieste, Italia
        • 205.372.39006 Boehringer Ingelheim Investigational Site
  • Lituania
      • Kaunas, Lituania
        • 205.372.37001 Boehringer Ingelheim Investigational Site
      • Kaunas, Lituania
        • 205.372.37003 Boehringer Ingelheim Investigational Site
      • Vilnius, Lituania
        • 205.372.37002 Boehringer Ingelheim Investigational Site
  • Malaysia
      • Johor Baharu, Malaysia
        • 205.372.60007 Boehringer Ingelheim Investigational Site
      • Kelantan Darul Naim, Malaysia
        • 205.372.60004 Boehringer Ingelheim Investigational Site
      • Kuala Lumpur, Malaysia
        • 205.372.60005 Boehringer Ingelheim Investigational Site
      • Kuala Lumpur, Malaysia
        • 205.372.60006 Boehringer Ingelheim Investigational Site
      • Kuching, Sarawak, Malaysia
        • 205.372.60002 Boehringer Ingelheim Investigational Site
      • Penang, Malaysia
        • 205.372.60003 Boehringer Ingelheim Investigational Site
      • Selangor, Malaysia
        • 205.372.60001 Boehringer Ingelheim Investigational Site
  • Messico
      • Chihuahua, Messico
        • 205.372.52018 Hospital Universitario de Chihuahua
      • Col. Seccion XVI, Messico
        • 205.372.52017 Instituto Nacional de Enfermedades Respiratorias (INER)
      • Cuernavaca, Mor. México, Messico
        • 205.372.52013 Sanatorio Henri Dunant
      • Guadalajara, Messico
        • 205.372.52005 Hospital Civil Nuevo de Guadalajara
      • Guadalajara Jal., Messico
        • 205.372.52009 Hospital Civil Antiguo
      • Hermosillo, Sonora, Messico
        • 205.372.52001 Hospital General del Estado de Sonora
      • Huixquilucan Edo.Mex., Messico
        • 205.372.52014 Hospital Angeles de las Lomas
      • Merida Yuc., Messico
        • 205.372.52004 Clínica de Mérida
      • Mexicali Baja California Norte, Messico
        • 205.372.52016 Hospital General de Mexicali
      • Monterrey, Nuevo León, Messico
        • 205.372.52002 Unidad de Investigación clínica en Medicina
      • Monterrey, Nuevo León, Messico
        • 205.372.52006 Hospital Universitario
      • Mérida Yucatán, Messico
        • 205.372.52010 Hospital General Agustin O´Haran
      • San Luis Potosi, Messico
        • 205.372.52012 Hospital de Nuestra Señora de la Salud
      • Zapopan, Jal., Messico
        • 205.372.52003 Hospital "Angel Leaño"
  • Norvegia
      • Sandvika, Norvegia
        • 205.372.47001 Boehringer Ingelheim Investigational Site
      • Trondheim, Norvegia
        • 205.372.47003 Boehringer Ingelheim Investigational Site
      • Ålesund, Norvegia
        • 205.372.47002 Boehringer Ingelheim Investigational Site
  • Olanda
      • Amsterdam, Olanda
        • 205.372.31009 Boehringer Ingelheim Investigational Site
      • Drachten, Olanda
        • 205.372.31006 Boehringer Ingelheim Investigational Site
      • Groningen, Olanda
        • 205.372.31001 Boehringer Ingelheim Investigational Site
      • Hoofddorp, Olanda
        • 205.372.31011 Boehringer Ingelheim Investigational Site
      • Leeuwarden, Olanda
        • 205.372.31007 Boehringer Ingelheim Investigational Site
      • Roosendaal, Olanda
        • 205.372.31004 Boehringer Ingelheim Investigational Site
      • Sneek, Olanda
        • 205.372.31003 Boehringer Ingelheim Investigational Site
      • Utrecht, Olanda
        • 205.372.31012 Boehringer Ingelheim Investigational Site
      • Voorburg, Olanda
        • 205.372.31002 Boehringer Ingelheim Investigational Site
      • Weerselo, Olanda
        • 205.372.31008 Boehringer Ingelheim Investigational Site
      • Winschoten, Olanda
        • 205.372.31005 Boehringer Ingelheim Investigational Site
  • Portogallo
      • Amadora, Portogallo
        • 205.372.35102 Hospital Fernando Fonseca
      • Lisboa, Portogallo
        • 205.372.35101 Hospital Pulido Valente
      • Lisboa, Portogallo
        • 205.372.35104 Hospital de Santa Marta
      • Porto, Portogallo
        • 205.372.35103 Hospital de São João
      • Viana do Castelo, Portogallo
        • 205.372.35105 Centro Hospitalar do Alto Minho, Estrada de Santa Luzia
  • Regno Unito
      • Aston Clinton, Aylesbury, Regno Unito
        • 205.372.44027 Boehringer Ingelheim Investigational Site
      • Carmarthen, Regno Unito
        • 205.372.44022 Boehringer Ingelheim Investigational Site
      • Chertsey, Regno Unito
        • 205.372.44002 Boehringer Ingelheim Investigational Site
      • Chesterfield, Regno Unito
        • 205.372.44023 Boehringer Ingelheim Investigational Site
      • Darlington, Regno Unito
        • 205.372.44014 Boehringer Ingelheim Investigational Site
      • East Horsley, Regno Unito
        • 205.372.44009 Boehringer Ingelheim Investigational Site
      • Fowey, Regno Unito
        • 205.372.44011 Boehringer Ingelheim Investigational Site
      • Frome, Regno Unito
        • 205.372.44003 Boehringer Ingelheim Investigational Site
      • Greenisland, Regno Unito
        • 205.372.44026 Boehringer Ingelheim Investigational Site
      • Heywood, Regno Unito
        • 205.372.44013 Boehringer Ingelheim Investigational Site
      • Isleworth, Regno Unito
        • 205.372.44016 Boehringer Ingelheim Investigational Site
      • Kirkby in Ashfield, Regno Unito
        • 205.372.44020 Boehringer Ingelheim Investigational Site
      • Mortimer, Regno Unito
        • 205.372.44024 Boehringer Ingelheim Investigational Site
      • Nottingham, Regno Unito
        • 205.372.44001 Boehringer Ingelheim Investigational Site
      • Penzance, Regno Unito
        • 205.372.44018 Boehringer Ingelheim Investigational Site
      • Plymouth, Regno Unito
        • 205.372.44021 Boehringer Ingelheim Investigational Site
      • Sheffield, Regno Unito
        • 205.372.44007 Boehringer Ingelheim Investigational Site
      • Sneinton, Nottingham, Regno Unito
        • 205.372.44010 Boehringer Ingelheim Investigational Site
      • St Just, Penzance, Regno Unito
        • 205.372.44005 Boehringer Ingelheim Investigational Site
      • St. Austell, Regno Unito
        • 205.372.44015 Boehringer Ingelheim Investigational Site
      • Sunderland, Regno Unito
        • 205.372.44006 Boehringer Ingelheim Investigational Site
      • Wellingborough, Regno Unito
        • 205.372.44008 Boehringer Ingelheim Investigational Site
      • Westbury on Trym, Regno Unito
        • 205.372.44012 Boehringer Ingelheim Investigational Site
      • Windsor, Regno Unito
        • 205.372.44028 Boehringer Ingelheim Investigational Site
      • Woking, Regno Unito
        • 205.372.44019 Boehringer Ingelheim Investigational Site
  • Singapore
      • Singapore, Singapore
        • 205.372.65001 Boehringer Ingelheim Investigational Site
      • Singapore, Singapore
        • 205.372.65003 Boehringer Ingelheim Investigational Site
      • Singapore, Singapore
        • 205.372.65005 Boehringer Ingelheim Investigational Site
  • Slovacchia
      • Bratislava, Slovacchia
        • 205.372.42102 Boehringer Ingelheim Investigational Site
      • Nove Zamky, Slovacchia
        • 205.372.42103 Boehringer Ingelheim Investigational Site
  • Spagna
      • Cáceres, Spagna
        • 205.372.34005 Hospital San Pedro de Alcántara
      • Madrid, Spagna
        • 205.372.34004 Hospital Gregorio Marañón
      • Madrid, Spagna
        • 205.372.34006 Hospital 12 de octubre
      • Terrassa (Barcelona), Spagna
        • 205.372.34001 Hospital Mutua Terrassa
      • Valencia, Spagna
        • 205.372.34002 Hospital Universitario Dr. Peset
  • Stati Uniti
    • Alabama
      • Birmingham, Alabama, Stati Uniti
        • 205.372.01012 Boehringer Ingelheim Investigational Site
      • Birmingham, Alabama, Stati Uniti
        • 205.372.01020 Boehringer Ingelheim Investigational Site
      • Mobile, Alabama, Stati Uniti
        • 205.372.01062 Boehringer Ingelheim Investigational Site
    • California
      • Berkeley, California, Stati Uniti
        • 205.372.01048 Boehringer Ingelheim Investigational Site
      • Huntington Park, California, Stati Uniti
        • 205.372.01037 Boehringer Ingelheim Investigational Site
      • Long Beach, California, Stati Uniti
        • 205.372.01058 Boehringer Ingelheim Investigational Site
      • Long Beach, California, Stati Uniti
        • 205.372.01059 Boehringer Ingelheim Investigational Site
      • Los Angeles, California, Stati Uniti
        • 205.372.01007 Boehringer Ingelheim Investigational Site
      • Los Angeles, California, Stati Uniti
        • 205.372.01034 Boehringer Ingelheim Investigational Site
      • Rancho Mirage, California, Stati Uniti
        • 205.372.01028 Boehringer Ingelheim Investigational Site
      • San Diego, California, Stati Uniti
        • 205.372.01011 Boehringer Ingelheim Investigational Site
    • Colorado
      • Boulder, Colorado, Stati Uniti
        • 205.372.01066 Boehringer Ingelheim Investigational Site
    • Connecticut
      • Norwalk, Connecticut, Stati Uniti
        • 205.372.01008 Boehringer Ingelheim Investigational Site
    • Florida
      • Brandon, Florida, Stati Uniti
        • 205.372.01004 Boehringer Ingelheim Investigational Site
      • Clearwater, Florida, Stati Uniti
        • 205.372.01060 Boehringer Ingelheim Investigational Site
      • Miami Beach, Florida, Stati Uniti
        • 205.372.01069 Boehringer Ingelheim Investigational Site
      • West Palm Beach, Florida, Stati Uniti
        • 205.372.01023 Boehringer Ingelheim Investigational Site
      • Winter Park, Florida, Stati Uniti
        • 205.372.01053 Boehringer Ingelheim Investigational Site
    • Georgia
      • Calhoun, Georgia, Stati Uniti
        • 205.372.01045 Boehringer Ingelheim Investigational Site
    • Illinois
      • Normal, Illinois, Stati Uniti
        • 205.372.01043 Boehringer Ingelheim Investigational Site
    • Iowa
      • Dubuque, Iowa, Stati Uniti
        • 205.372.01061 Boehringer Ingelheim Investigational Site
    • Kansas
      • Wichita, Kansas, Stati Uniti
        • 205.372.01035 Boehringer Ingelheim Investigational Site
    • Louisiana
      • Shreveport, Louisiana, Stati Uniti
        • 205.372.01049 Boehringer Ingelheim Investigational Site
    • Maine
      • Biddeford, Maine, Stati Uniti
        • 205.372.01015 Boehringer Ingelheim Investigational Site
    • Maryland
      • Columbia, Maryland, Stati Uniti
        • 205.372.01067 Boehringer Ingelheim Investigational Site
      • Rockville, Maryland, Stati Uniti
        • 205.372.01006 Boehringer Ingelheim Investigational Site
    • Michigan
      • Detroit, Michigan, Stati Uniti
        • 205.372.01013 Boehringer Ingelheim Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti
        • 205.372.01003 Boehringer Ingelheim Investigational Site
    • Missouri
      • Chesterfield, Missouri, Stati Uniti
        • 205.372.01021 Boehringer Ingelheim Investigational Site
      • St. Louis, Missouri, Stati Uniti
        • 205.372.01014 Boehringer Ingelheim Investigational Site
    • Nebraska
      • Omaha, Nebraska, Stati Uniti
        • 205.372.01036 Boehringer Ingelheim Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti
        • 205.372.01046 Boehringer Ingelheim Investigational Site
    • New York
      • Mineola, New York, Stati Uniti
        • 205.372.01024 Boehringer Ingelheim Investigational Site
      • Rochester, New York, Stati Uniti
        • 205.372.01029 Boehringer Ingelheim Investigational Site
      • Syracuse, New York, Stati Uniti
        • 205.372.01030 Boehringer Ingelheim Investigational Site
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti
        • 205.372.01026 Boehringer Ingelheim Investigational Site
      • Charlotte, North Carolina, Stati Uniti
        • 205.372.01019 Boehringer Ingelheim Investigational Site
      • Elizabeth City, North Carolina, Stati Uniti
        • 205.372.01027 Boehringer Ingelheim Investigational Site
      • Raleigh, North Carolina, Stati Uniti
        • 205.372.01038 Boehringer Ingelheim Investigational Site
      • Winston-Salem, North Carolina, Stati Uniti
        • 205.372.01031 Boehringer Ingelheim Investigational Site
    • Ohio
      • Cincinnati, Ohio, Stati Uniti
        • 205.372.01017 Boehringer Ingelheim Investigational Site
      • Cincinnati, Ohio, Stati Uniti
        • 205.372.01041 Boehringer Ingelheim Investigational Site
      • Cincinnati, Ohio, Stati Uniti
        • 205.372.01044 Boehringer Ingelheim Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti
        • 205.372.01001 Boehringer Ingelheim Investigational Site
    • Oregon
      • Eugene, Oregon, Stati Uniti
        • 205.372.01063 Boehringer Ingelheim Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti
        • 205.372.01068 Boehringer Ingelheim Investigational Site
      • Swathmore, Pennsylvania, Stati Uniti
        • 205.372.01056 Boehringer Ingelheim Investigational Site
    • Texas
      • Dallas, Texas, Stati Uniti
        • 205.372.01039 Boehringer Ingelheim Investigational Site
      • Dallas, Texas, Stati Uniti
        • 205.372.01050 Boehringer Ingelheim Investigational Site
      • Fort Worth, Texas, Stati Uniti
        • 205.372.01005 Boehringer Ingelheim Investigational Site
      • Killeen, Texas, Stati Uniti
        • 205.372.01018 Boehringer Ingelheim Investigational Site
      • New Braunfels, Texas, Stati Uniti
        • 205.372.01040 Boehringer Ingelheim Investigational Site
      • San Antonio, Texas, Stati Uniti
        • 205.372.01052 Boehringer Ingelheim Investigational Site
    • Virginia
      • Danville, Virginia, Stati Uniti
        • 205.372.01022 Boehringer Ingelheim Investigational Site
      • Lynchburg, Virginia, Stati Uniti
        • 205.372.01065 Boehringer Ingelheim Investigational Site
      • Richmond, Virginia, Stati Uniti
        • 205.372.01055 Boehringer Ingelheim Investigational Site
    • Washington
      • Tacoma, Washington, Stati Uniti
        • 205.372.01064 Boehringer Ingelheim Investigational Site
  • Sud Africa
      • Bellville, Sud Africa
        • 205.372.27002 Boehringer Ingelheim Investigational Site
      • Cape Town, Sud Africa
        • 205.372.27001 Boehringer Ingelheim Investigational Site
      • Cape Town, Sud Africa
        • 205.372.27004 Boehringer Ingelheim Investigational Site
      • Cape Town, Sud Africa
        • 205.372.27008 Boehringer Ingelheim Investigational Site
      • Centurion, Sud Africa
        • 205.372.27006 Boehringer Ingelheim Investigational Site
      • Durban, Sud Africa
        • 205.372.27003 Boehringer Ingelheim Investigational Site
      • Pretoria, Sud Africa
        • 205.372.27005 Boehringer Ingelheim Investigational Site
      • Somerset West, Sud Africa
        • 205.372.27007 Boehringer Ingelheim Investigational Site
  • Svezia
      • Boden, Svezia
        • 205.372.46001 Björknäs Vårdcentral
      • Höllviken, Svezia
        • 205.372.46004 Näsets läkargrupp
      • Linköping, Svezia
        • 205.372.46005 Lungmedicinska kliniken
      • Stockholm, Svezia
        • 205.372.46006 Lungmedicinska Kliniken
      • Sundsvall, Svezia
        • 205.372.46002 Alnö Vårdcentral
  • Svizzera
      • Lugano, Svizzera
        • 205.372.41002 Boehringer Ingelheim Investigational Site
      • Montana, Svizzera
        • 205.372.41003 Boehringer Ingelheim Investigational Site
      • Zürich, Svizzera
        • 205.372.41001 Boehringer Ingelheim Investigational Site
  • Tacchino
      • Ankara, Tacchino
        • 205.372.90006 Gazi Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.
      • Ankara, Tacchino
        • 205.372.90007 Atatürk Gög. Hastaliklari ve Cerrahisi Egitim Hastanesi
      • Bursa, Tacchino
        • 205.372.90003 Uludag Universitesi Tip Fakultesi Gogus Hastaliklari
      • Edirne, Tacchino
        • 205.372.90009 Trakya Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.
      • Istanbul, Tacchino
        • 205.372.90004 Dr. Lütfi Kirdar Egitim ve Arastirma Hastanesi
      • Istanbul, Tacchino
        • 205.372.90005 Istanbul Universitesi Cerrahpasa Tip Fakultesi
      • Izmir, Tacchino
        • 205.372.90001 Izmir Tepecik Gogus Hastaliklari ve Gogus Cerrahisi Hast.
      • Kayseri, Tacchino
        • 205.372.90008 Erciyes Universitesi Tip Fakultesi
      • Konya, Tacchino
        • 205.372.90010 Selcuk Universitesi Tip Fakultesi
      • Samsun, Tacchino
        • 205.372.90002 19 Mayis Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D
  • Taiwan
      • Kaohsiung, Taiwan
        • 205.372.88607 Kaohsiung Medical University Hospital
      • Tainan, Taiwan
        • 205.372.88606 National Cheng Kung University Hospital
      • Taipei, Taiwan
        • 205.372.88601 National Taiwan University Hospital
      • Taipei, Taiwan
        • 205.372.88602 Taipei Veterans General Hospital
      • Taipei, Taiwan
        • 205.372.88603 Mackay Memorial Hospital
      • Taipei, Taiwan
        • 205.372.88604 Tri-Service General Hospital
      • Taipei, Taiwan
        • 205.372.88608 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 205.372.88609 Boehringer Ingelheim Investigational Site
      • Taoyuan, Taiwan
        • 205.372.88605 Chang Gung Memorial Hosp-Linkou
  • Ungheria
      • Budapest, Ungheria
        • 205.372.36001 Boehringer Ingelheim Investigational Site
      • Debrecen, Ungheria
        • 205.372.36002 Boehringer Ingelheim Investigational Site
      • Deszk, Ungheria
        • 205.372.36004 Boehringer Ingelheim Investigational Site
      • Erd, Ungheria
        • 205.372.36005 Boehringer Ingelheim Investigational Site
      • Mosonmagyarovar, Ungheria
        • 205.372.36006 Boehringer Ingelheim Investigational Site
      • Sopron, Ungheria
        • 205.372.36007 Boehringer Ingelheim Investigational Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

40 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Male or female
  2. At least 40 years old
  3. Smoker or ex-smoker
  4. Smoking history > 10 pack-years
  5. Forced Expiratory Volume in 1 Second (FEV1) < 60% predicted

Exclusion Criteria:

  1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure
  2. History of asthma or allergic conditions.
  3. Malignancy requiring treatment within past 5 years
  4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis
  5. Known active tuberculosis
  6. Known hypersensitivity to anticholinergic drugs.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Modello interventistico: Assegnazione parallela

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Altro: Tiotropium
Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
Droga: Tiotropio
Altro: Placebo
Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
Dispositivo: Respimat

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337
Lasso di tempo: Baseline and Day 337
Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).
Baseline and Day 337
Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Time to first COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation.
During actual study treatment period (planned Day 1 to Day 337)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29
Lasso di tempo: Baseline and Day 29
Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.
Baseline and Day 29
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169
Lasso di tempo: Baseline and Day 169
Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.
Baseline and Day 169
Number of COPD Exacerbations Per Patient - Exposure Adjusted
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. number of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)
During actual study treatment period (planned Day 1 to Day 337)
Number of COPD Exacerbations Per Patient - naïve Estimate
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)
During actual study treatment period (planned Day 1 to Day 337)
Number of Patients With at Least One COPD Exacerbation
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Number of patients with at least one COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)
During actual study treatment period (planned Day 1 to Day 337)
Time to First Hospitalisation for COPD Exacerbation
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Time to first hospitalisation for COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation
During actual study treatment period (planned Day 1 to Day 337)
Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. no. of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)
During actual study treatment period (planned Day 1 to Day 337)
Number of Hospitalisations for COPD Exacerbations Per Patient - naïve Estimate
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)
During actual study treatment period (planned Day 1 to Day 337)
Number of Patients With at Least One Hospitalisation for a COPD Exacerbation
Lasso di tempo: During actual study treatment period (planned Day 1 to Day 337)
Number of patients with at least one hospitalisation for a COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)
During actual study treatment period (planned Day 1 to Day 337)
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337
Lasso di tempo: Baseline and Day 337
The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Baseline and Day 337
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169
Lasso di tempo: Baseline and Day 169
The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Baseline and Day 169
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 337
Lasso di tempo: Baseline and Day 337
The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Baseline and Day 337
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 169
Lasso di tempo: Baseline and Day 169
The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Baseline and Day 169
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29
Lasso di tempo: Baseline and Day 29
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Baseline and Day 29
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169
Lasso di tempo: Baseline and Day 169
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Baseline and Day 169
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337
Lasso di tempo: Baseline and Day 337
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Baseline and Day 337
Marked Changes From Baseline in Vital Signs at End of Treatment
Lasso di tempo: Baseline and end of treatment

Marked changes from baseline in vital signs (diastolic and systolic blood pressure (DBP and SBP) and pulse rate (PR)) at end of treatment.

SBP - Increase means SBP >150 mmHg and an increase above baseline of >25 mmHg. SBP - Decrease means SBP <100 mmHg and a decrease below baseline of >10 mmHg.

DBP - Increase means DBP >90 mmHg and an increase above baseline of >10 mmHg. DBP - Decrease means DBP <60 mmHg and a decrease below baseline of >10 mmHg.

PR - Increase means PR >100 bpm and an increase above baseline of >10 bpm. PR - Decrease means PR <60 bpm and a decrease below baseline of >10 bpm.
Baseline and end of treatment
Clinically Relevant Findings in Physical Examination and ECG
Lasso di tempo: End of treatment
Clinically relevant findings in Physical Examination and ECG at end of treatment
End of treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Boehringer Ingelheim

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 settembre 2006

Completamento primario (Effettivo)

1 gennaio 2009

Date di iscrizione allo studio

Primo inviato

11 ottobre 2006

Primo inviato che soddisfa i criteri di controllo qualità

11 ottobre 2006

Primo Inserito (Stima)

12 ottobre 2006

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

16 maggio 2014

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 maggio 2014

Ultimo verificato

1 settembre 2013

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 205.372
  • 2006-001009-27

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Macedonia

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi